• Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

  • Sep 10 2024
  • Length: 19 mins
  • Podcast

Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

Listen for free

View show details

  • Summary

  • Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso is the latest company with a bispecific to impress in a head-to-head study, this one for non-small cell lung cancer. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest data from Akeso’s ivonescimab, a VEGFxPD-1 bispecific antibody that went up against Keytruda pembrolizumab in one of its largest indications, first-line non-small cell lung cancer.
    The editors also discuss data from Vaxcyte that the infectious disease company parlayed into the year’s largest follow-on financing and a new initiative by FDA veteran Janet Woodcock to bolster quality in biopharmas’ manufacturing. This episode of BioCentury This Week was sponsored by Parexel Biotech.

    View full story: https://www.biocentury.com/article/653507

    00:01 - Sponsor Message: Parexel Biotech
    01:39 - Akeso's Bispecific Challenge
    08:22 - Vaxcyte Pneumococcal Vaccine
    12:32 - Woodcock's Quality Initiative
    14:48 - Recap: The BioCentury Show on Biosimilars

    Reach us by sending a text
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available